
    
      This is an open-label, non-randomized study of approximately 80 patients. Enrollment into
      each cohort will occur independently, with 50 programmed cell death ligand 1 (PD-L1)-positive
      patients enrolled in the retifanlimab cohort, and 30 PD-L1-negative patients enrolled in the
      tebotelimab cohort.
    
  